Trial registered testing Jornay PM for ADHD with cannabis use disorder in young people

This week's only Collegium-linked item is a newly registered investigator-sponsored trial, with the company listed as a collaborator rather than the study sponsor.

• **Jornay PM (delayed-release, extended-release methylphenidate), Phase 4, ADHD with co-occurring cannabis use disorder**: The study is a phase4, randomized, parallel-group trial with an estimated enrollment of 66 participants¹, sponsored by Massachusetts General Hospital with the National Institute on Drug Abuse and Collegium Pharmaceutical, Inc. as collaborators. Status is listed as not yet recruiting, with an estimated start of November 2026 and primary completion in November 2029. Participants will be randomized to take Jornay PM or a matching placebo nightly for 12 weeks, in adolescents and young adults ages 16 to 26 with ADHD and Cannabis Use Disorder.¹ The primary outcome is change in ADHD symptom severity as measured by the Adult ADHD Investigator Symptom Rating Scale from baseline to week 12¹.